Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 20, 2009

OriGene Acquires Marligen to Fortify Gene-Centric Toolbox

  • OriGene Technologies is taking over Marligen Biosciences to enhance its gene-centric product portfolio. Marligen adds an array of assay panels and custom assays for drug discovery.

    Marligen provides protein and gene-expression profiling assays and testing services for the Luminex xMAP® platform as well as DNA and RNA purification kits. OriGene aims to couple these assays and reagents with its high-throughput mAb production capabilities to further develop high-quality panels and offer customization to hasten and increase efficiencies for drug discovery.

    OriGene's mammalian cell-expressed proteins reportedly maintain authentic protein structure, post-translational modifications, and functions. The firm’s product line includes what is reportedly the largest cDNA and shRNA clone collections of over 5,000 purified human proteins, high-quality mAbs to human proteins, 100,000 highly validated human tissues, and qPCR arrays. OriGene also provides antibody-validation products including genome-wide tagged antigen standards and extensive IHC slides derived from its tissue collection.


Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »